Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	54.67B +12.5%
Revenue (ttm)	7.60B +3.5%
Net Income	988.05M +119.2%
EPS	1.15 +121.0%
Shares Out	n/a
PE Ratio	55.33
Forward PE	50.82
Dividend	0.32 (0.74%)
Ex-Dividend Date	Jun 12, 2025

Volume	1,442,400
Average Volume	1,944,260
Open	43.08
Previous Close	43.08
Day's Range	42.62 - 44.38
52-Week Range	24.55 - 60.60
Beta	0.68
RSI	51.38
Earnings Date	Mar 30, 2026

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2025, HKG:3347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY